Research Study

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Principal Investigator 
John Swiston

Overview

Body Locations and Systems 
Pulmonary Hypertension
ClinicalTrials.gov# 
NCT03626688
Status 
Recruiting
Study Start/End 
Sep 16, 2019 to Dec 31, 2021
Locations 
Diamond Health Care Centre
Name/Title 
Mami Okada, Research Coordinator
Phone 
604-875-4111 ext.69831
Email Address 
mami.okada@vch.ca
Purpose of Study 

The purpose of this study is to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.